New Provider Conference

The second day of Provider was focused toward the additive manufacturing, we had the presence of Samylabs, a company dedicated to the design, manufacture and marketing of metal 3D printers with laser beam powder fusion technology.

VRAINHAX at Fisio Expo 2023

On 27th, 28th and 29th October the VRAINHAX team attended FISIOEXPO’23, the largest physiotherapy event in Europe, where they were able to present their innovative tool for the rehabilitation of various pathologies in immersive environments through gamified experiences.

4th Basque Electromedicine Forum

Last Friday, the 4th Basque Electromedicine Forum was held at the Cruces University Hospital and was presented and conducted by Nagore Fernández, CEO and founder of Biometriks and based at BIC Bizkaia.

Philips Ventures Visit

Yesterday we received at the BIC the visit of two representatives of the Philips Ventures corporate fund for investment in health startups.

II. Pintxo BIC Bizkaia

On Friday we hosted the second PINTXO BIC BIZKAIA gathering at our incubator and got to know a little more about the work of DRONE BY DRONE, INSEKT LABEL and MIKROBIOMIK. On this occasion, we had the pleasure of meeting […]

Seoul Business Agency Visit

As part of the visit to Bizkaia of the Seoul Business Agency (SBA), yesterday we received their representatives at the BIC Bizkaia.

Startup Wise Guys Visit

Yesterday we received at BIC the visit of the startup accelerator Wise Guys, who had the opportunity to get to know closely two veteran companies of our centre.


Last friday we held the first PINTXO BIC BIZKAIA meeting and we met projects that have recently joined our centre such as INNOMY, VENTIJET and SENSTILE.

Mikrobiomik closes 1.1 million capital increase

In a huge step towards the evolution of medical research, Mikrobiomik, the pioneer company in the human microbiome, has confirmed a capital increase of 1.1 million euros. This milestone happens thanks to the exclusive contribution of its current partners, who are determined to accomplish their initial mission: to launch their investigational biological drug, MBK 01, on the European market.

There are no upcoming events at this time.